Many Spectrum Pharmaceuticals, Inc.(SPPI) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Spectrum Pharmaceuticals was Resumed by Jefferies to Buy on Feb 10, 2017.
Spectrum Pharmaceuticals Last issued its quarterly earnings results on Aug 9, 2016. The company reported $-0.05 EPS for the quarter, beating the analyst consensus estimate by $ 0.12. Analyst had a consensus of $-0.17. The company had revenue of $33.90 million for the quarter, compared to analysts expectations of $30.88 million. The companys revenue was down -24.6 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.01 EPS.
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1 by 3 Brokerage Firm. 3 Wall Street Firms have rated the stock as a strong buys.
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) shares are expected to touch $9.17 in the short term. This short term price target has been shared by 3 analysts. However, the standard deviation of short term price estimate has been valued at 1.44. The target price could hit $10 on the higher end and $8 on the lower end.
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) rose 5.33% or 0.29 points on Tuesday and made its way into the gainers of the day. After trading began at $5.45 the stock was seen hitting $5.84 as a peak level and $5.45 as the lowest level. The stock ended up at $5.73. The daily volume was measured at 680,867 shares. The 52-week high of the share price is $7.74 and the 52-week low is $3.21. The company has a market cap of $462 million.
Spectrum Pharmaceuticals, Inc. is opportunistically acquiring and advancing a diversified portfolio of oncology drug candidates that meet critical health challenges for which there are few other treatment options. Spectrums expertise lies in identifying undervalued drugs with demonstrated safety and efficacy, and adding value through further clinical development and selection of the most viable and low-risk methods of commercialization. The companys pipeline includes promising early and late-stage drug candidates with unique formulations and mechanisms of action that address the needs of seriously ill patients, such as at-home chemotherapy and new treatment regimens for refractory disease.